What is the recommended dosing schedule for Apretude?

Apretude is a long-acting injectable formulation of cabotegravir, used for the prevention of HIV. The recommended dosing schedule is every two months, which aligns with its pharmacokinetic properties allowing for sustained drug levels necessary for effective pre-exposure prophylaxis (PrEP). This dosing interval helps maintain adequate drug concentration in the body while providing convenience and improving adherence compared to daily dosing regimens.

Daily dosing, while effective for some other forms of PrEP, is less convenient and can lead to adherence issues. Monthly and three-month schedules do not align with the pharmacological data supporting Apretude's use, making the bi-monthly schedule the optimal choice for maintaining efficacy and encouraging compliance among patients.